Clinical studies have shown that 18F-FES PET can reliably detect ER+ breast cancer lesions and that 18F-FES uptake correlates well with ERα immunohistochemical (IHC) scoring [14–16]. This evidence concerns the gene ESR1 and breast carcinoma.